BAZEDOXIFENE ACETATE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated in postmenopausal osteoporosis and has 3 investigational indications. Its therapeutic use is listed as anti-osteoporosis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Duavive, Brilence and Viviant (TN). Its PubChem CID is 154256.
Bazedoxifene acetate
| CAS No | 198481-33-3 |
|---|---|
| Molecular Formula | C32H38N2O5 |
| Molecular Weight | 530.7 g/mol |
| Synonyms | acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
BAZEDOXIFENE ACETATE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and is indicated in postmenopausal osteoporosis and has 3 investigational indications.
The listed CAS number is 198481-33-3.
The listed molecular formula is C32H38N2O5.
The listed molecular weight is 530.7 g/mol.
acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol.
The source lists Duavive, Brilence and Viviant (TN).